Knight to Present at Stifel GMP’s The Future of Healthcare Conference
MONTREAL, Dec. 02, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, is pleased to announce that Samira Sakhia, President and Chief Executive Officer, is scheduled to present at the upcoming Stifel GMP Future of Healthcare Conference on Wednesday, December 8, 2021 at 10 am ET, that will be […]
Knight Therapeutics Reports Third Quarter 2021
— Achieves Record Quarterly Revenues — MONTREAL, Nov. 11, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its third quarter ended September 30, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are […]
Notice of Knight Therapeutics’ Third Quarter 2021 Results Conference Call
MONTREAL, Nov. 04, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2021 financial results on Thursday, November 11, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight Therapeutics Inc. places No. 27 on The Globe and Mail’s third-annual ranking of Canada’s Top Growing Companies
MONTREAL, Sept. 24, 2021 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 27 on the 2021 Report on Business ranking of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 2,211%. “We are […]
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Incyte for Tafasitamab and Pemigatinib in Latin America
MONTREAL, Sept. 23, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), for the exclusive rights to distribute tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in […]
Knight Therapeutics Reports Second Quarter 2021
— Achieves Record Quarterly Revenues — MONTREAL, Aug. 13, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading Pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2021. All currency amounts are in thousands except for share and per share amounts. All currencies are […]
Notice of Knight Therapeutics’ Second Quarter 2021 Results Conference Call
MONTREAL, Aug. 06, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2021 financial results on Friday, August 13, 2021 prior to market opening. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate […]
Knight to Present at the Canaccord Genuity 41st Annual Growth Conference
MONTREAL, Aug. 05, 2021 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President and Chief Operating Officer, is scheduled to present at Canaccord Genuity 41st Annual Growth Conference on Wednesday, August 11, 2021 at 3:00 pm ET, that will be held virtually. A copy […]
Knight Announces Normal Course Issuer Bid
MONTREAL, July 12, 2021 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company“), a leading pan-American (ex-US) specialty pharmaceutical company, announced today acceptance by the Toronto Stock Exchange (the “TSX”) of the Company’s Notice of Intention to Make a Normal Course Issuer Bid (“NCIB”). Pursuant to the NCIB, the Company proposes to purchase, from time […]
Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer
MONTREAL, July 06, 2021 — Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The […]
